Risk of medication-related osteonecrosis of the jaw during romosozumab treatment - PubMed
3 hours ago
- #Osteoporosis
- #Romosozumab
- #MRONJ
- MRONJ is a rare but important adverse event in osteoporosis treatment.
- Romosozumab, a dual-action osteoporosis drug, was compared to PTH analogs for MRONJ risk.
- A retrospective cohort study of 15,689 matched patients per group found no significant difference in MRONJ incidence.
- The hazard ratio for MRONJ was 0.89, indicating no detectable excess risk with romosozumab.
- Absolute event rates were very low: 0.070% for romosozumab and 0.076% for PTH analogs.
- Hypercalcemia occurred less often with romosozumab, serving as a positive control.
- Study limitations include rare events, potentially masking modest risk differences.